MetaStat is a biotechnology company focused on discovering and developing personalized diagnostic and therapeutic treatment solutions for cancer patients. Unlike surrogate cancer markers, which are indirect measures of cancer and its progression, driver-based biomarkers are the critical components of intracellular cancer pathways responsible for driving the aggressive activity of cancer cells. The Company's core expertise includes an understanding of the mechanisms and pathways that drive aggressive cancer, tumor cell invasion and metastasis.